MIF - Spinal Cord Injury Study
GCRC 0268:Pilot Study: The Role of MIF in Spinal Cord Injury
Protocol ID
Protocol Description
The purpose of this study is to evaluate substances that may be present in the blood after a spinal cord injury (SCI). Specifically, the study will evaluate the presence and levels of a protein, macrophage migration inhibitory factor (MIF), in the blood of patients who have had a SCI. Blood samples from patients who have had a SCI and uninjured individuals will be studied to measure MIF levels. MIF is released by cells and has a specific effect on the way cells behave, communicate and work together. In several other medical conditions, MIF is known to increase inflammation in the body. By comparing blood samples from spinal cord injury patients and normal uninjured individuals, the investigators will try to find out if MIF levels are increased in people with SCI. Investigators will also use these samples to see if the biological activities of MIF can be reduced in a test tube by adding other substances to the blood samples. It is hoped that this study of MIF will help improve the treatment of SCI in the future. Other factors in the blood, including inflammatory proteins and hormones (substances that can affect MIF levels), will be tested.
Eligibility Criteria
Patients who have had a spinal cord injury
Primary Investigator(s)
- Ona Bloom, PhD